Key result
Insulin provision therapy increased the hazard of fatal or nonfatal myocardial infarction by 3.2-fold compared to insulin sensitization therapy in actively smoking patients with type 2 diabetes and stable ischemic heart disease.
Why the study?
Does insulin provision therapy increase the risk of fatal or nonfatal myocardial infarction in actively smoking patients with diabetes mellitus and stable ischemic heart disease compared to insulin sensitization therapy?
RCT (n=295)
Stratified by method of revascularization (PCI or CABG)
Yes
Does insulin provision therapy increase the risk of fatal or nonfatal myocardial infarction in actively smoking patients with diabetes mellitus and stable ischemic heart disease compared to insulin sensitization therapy?
In actively smoking patients with diabetes and stable ischemic heart disease, insulin provision therapy significantly increases the risk of myocardial infarction compared to insulin sensitization therapy, potentially due to increased PAI-1 activity.
Answers are grounded in this paper and cite their sources.
Warrants avoiding insulin provision in actively smoking patients with T2D and stable ischemic heart.
Background In the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial, randomization of diabetic patients with stable ischemic heart disease to insulin provision ( IP ) therapy, as opposed to insulin sensitization ( IS ) therapy, resulted in biochemical evidence of impaired fibrinolysis but no increase in adverse clinical outcomes. We hypothesized that the prothrombotic effect of IP therapy in combination with the hypercoagulable state induced by active smoking would result in an increased risk of myocardial infarction ( MI ). Methods and Results We analyzed BARI 2D patients who were active smokers randomized to IP or IS therapy. The primary end point was fatal or nonfatal MI . PAI ‐1 (plasminogen activator inhibitor 1) activity was analyzed at 1, 3, and 5 years. Of 295 active smokers, MI occurred in 15.4% randomized to IP and in 6.8% randomized to IS over the 5.3 years ( P =0.023). IP therapy was associated with a 3.2‐fold increase in the hazard of MI compared with IS therapy (hazard ratio: 3.23; 95% confidence interval, 1.43–7.28; P =0.005). Baseline PAI ‐1 activity (19.0 versus 17.5 Au/mL, P =0.70) was similar in actively smoking patients randomized to IP or IS therapy. However, IP therapy resulted in significantly increased PAI ‐1 activity at 1 year (23.0 versus 16.0 Au/mL, P =0.001), 3 years (24.0 versus 18.0 Au/mL, P =0.049), and 5 years (29.0 versus 15.0 Au/mL, P =0.004) compared with IS therapy. Conclusions Among diabetic patients with stable ischemic heart disease who were actively smoking, IP therapy was independently associated with a significantly increased hazard of MI . This finding may be explained by higher PAI ‐1 activity in active smokers treated with IP therapy. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00006305.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2017) conducted an RCT in Type 2 diabetes mellitus and stable ischemic heart disease in active smokers (n=295). Insulin provision therapy vs. Insulin sensitization therapy was evaluated on Fatal or nonfatal myocardial infarction (HR 3.23, 95% CI 1.43-7.28, p=0.005). Insulin provision therapy increased the hazard of fatal or nonfatal myocardial infarction by 3.2-fold compared to insulin sensitization therapy in actively smoking patients with type 2 diabetes and stable ischemic heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: